Pigeon Inactivated Vaccine (PMV-1+Salm+PiAdV)
- For the prevention of Newcastle disease, Salmonella infections, and pigeon adenovirus type I infection in pigeons.
- Manufacturing: Produced in GMP-certified facility
- Supply Mode: Bulk Supply / Distributor / OEM Available
- Origin: China
Generic Name
Pigeon Inactivated Vaccine (PMV-1+Salm+PiAdV)
Composition and Content
| Disease Name | Strain | Content |
|---|---|---|
| PMV-1 | PPMV-1 | ≥ 108.0 EID50/0.1mL |
| Salm | KOS061084 | ≥ 108.0 EID50/0.1mL |
| PiAdV | PiAdV-1/2 | PiAdV-1/2 ≥ 107.5 TCID50/dose |
Indications
For the prevention of Newcastle disease, Salmonella infections, and pigeon adenovirus type I infection in pigeons. Primary immunization is recommended for pigeons 4 weeks of age and older. Booster immunization should be administered every 6-12 months. Immunity lasts approximately 6-12 months.
Dosage and Administration
Administer by intramuscular injection into the chest or by subcutaneous injection in the dorsal neck region at 0.3-0.5 mL per bird. The recommended immunization schedule is as follows:
Young Pigeons
At 4 weeks of age: Primary immunization with live Newcastle disease (ND) vaccine by nasal or eye drops.
At 6-8 weeks of age: Booster immunization with this trivalent inactivated vaccine.
Adult Pigeons
Administer a booster dose every 6 months.
Breeding Pigeons
Administer a booster dose 3-4 weeks before pairing.
Racing Pigeons
Administer a booster dose 3-4 weeks before the racing season.
Adverse Reactions
Generally, no visible adverse reactions occur.
Specification
100 mL/bottle.
Appearance
A milky-white or light-yellow oil emulsion. Slight stratification may occur upon standing; shake well before use.
Storage and Shelf Life
Store at 2-8°C. Shelf life: 18 months.
1. Dual-Strain Broad Protection
- 1. One injection provides four protections – an innovative breakthrough in China that improves disease prevention efficiency, enhances effectiveness, and reduces farm workload.
- 2. Serotype-matched, highly concentrated viral subunit antigens formulated in scientifically optimized proportions.
- 3. Adjuvant formulation ensures zero stress and delivers high-efficiency protection using compound vegetable oil technology.
- 4. The vaccine contains composite antigens from classical very virulent Infectious Bursal Disease virus (cvvIBDV) and novel variant IBDV (nvIBDV), offering improved cross-protection against both strains as an upgraded version of the company’s original inactivated IBD vaccine series.
- 5. The adoption of a customized H9 Avian Influenza strain model enables meeting the needs of different countries for prevalent strains.